Matter Bio has created a clinical‑stage immuno‑oncology platform that makes hard‑to‑treat solid tumors visible to the immune system by recruiting memory T cells into the tumor microenvironment. The technology delivers familiar immune signals to tumors, aiming for controlled exposure and tolerability, with its first therapeutic program targeting metastatic pancreatic cancer. By turning hidden tumors into actionable targets, the platform seeks to enable powerful yet manageable immune‑based cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Hard-to-treat solid tumors such as metastatic pancreatic cancer are immunologically “cold,” making them difficult to detect early and resistant to existing immunotherapies, which results in low survival rates and limited treatment options.
Solution
Matter Bio’s clinical‑stage platform delivers established immune‑activating signals directly into the tumor microenvironment to recruit and activate memory T cells against these hidden cancers. By making the tumor visible to the immune system, the approach aims to generate a potent yet tolerable anti‑tumor response. The platform is engineered for controlled exposure, allowing sustained immune activity while minimizing systemic toxicity. Early clinical focus on metastatic pancreatic cancer seeks to transform a disease with poor prognosis into a manageable condition through durable immune control.
Target Audience
Primary customers are oncology pharmaceutical companies and clinical research organizations developing therapies for hard‑to‑treat solid tumors, as well as oncologists seeking novel immuno‑oncology options for patients with metastatic pancreatic cancer.
Features
- Engineered delivery of familiar immune signals that specifically target solid tumor sites
- Recruitment and activation of memory T cells to convert immunologically cold tumors into hot, responsive lesions
- Controlled exposure design to balance efficacy with tolerability for long‑term disease management
- Platform architecture that enables repeatable dosing and potential applicability across multiple solid tumor types
- Integration of tumor‑directed immune activation to enhance visibility of otherwise hidden cancer cells